Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Lance Pagliaro

Medical Oncology Rochester, MN Medical Doctor

NPI 1568553311 CMS profile 862867

200 1St St Sw, Rochester, MN 55905

Open in the dashboard

General payments

$18,378

20 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$5,074,016 paid to institutions, not to them · program years 2019–2025

Through program year 2022, Lance Pagliaro of Rochester, MN is reported in the CMS Open Payments database as having received $18,378 across 20 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $5,074,016 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 71st percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $2,135 1
2021 General $1,500 1
2020 General $5,438 3
2019 General $9,305 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lance Pagliaro
  • Medical Oncology median
  • Middle half of Medical Oncology
  • National median

In program year 2025, general payments to Lance Pagliaro were reported at $0. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.

Show as a table
Year Lance Pagliaro Medical Oncology median Middle half National median
2019 $9,305 $968 $140–$6,658 $163
2020 $5,438 $747 $102–$5,891 $114
2021 $1,500 $430 $50–$4,098 $132
2022 $2,135 $812 $127–$4,907 $149
2023 $0 $957 $144–$5,248 $160
2024 $0 $1,042 $149–$5,650 $164
2025 $0 $1,128 $147–$5,675 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Merck Sharp & Dohme Corporation $14,440 18 payments
  2. Astellas Pharma Global Development $3,938 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Consulting Fee $16,573 7 payments
  2. Travel and Lodging $1,454 6 payments
  3. Food and Beverage $351 7 payments
Products named General payments · program years 2019–2022
  1. PADCEV $3,938 2 payments
  2. KEYTRUDA $141 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

363

Median for Medical Oncology: 414

Drug cost

$2,440,924

Median for Medical Oncology: $849,427

Branded share of claims

36.1%

Median for Medical Oncology: 28.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtandi Enzalutamide Brand 65 $879,298
Cabometyx Cabozantinib S-Malate Brand 27 $756,707
Inlyta Axitinib Brand 18 $338,977
Erleada Apalutamide Brand 21 $330,340
Abiraterone Acetate Generic 30 $134,117
Prochlorperazine Maleate Generic 33 $382
Dexamethasone Generic 43 $290
Olanzapine Generic 40 $285
Ondansetron Hcl Generic 39 $227
Oxycodone Hcl Generic 19 $145

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,431 Part D prescribers listed as Medical Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 108 billing codes

Paid by Medicare

$791,973

Of which drugs: $743,435

Medicare patients

271

Average age 74

Services billed

33,904

101 women, 170 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Cancer 61%
Arthritis 39%
Chronic kidney disease 38%
Ischemic heart disease 30%
Diabetes 26%
Atrial fibrillation 24%
Heart failure 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, daratumumab, 10 mg and hyaluronidase-fihj J9144 Office 21 3,783 $149,047
Injection, pembrolizumab, 1 mg J9271 Office 15 3,500 $146,716
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 13 55 $7,701
Injection, bortezomib (velcade), 0.1 mg J9041 Office 11 485 $719
Injection, palonosetron hcl, 25 mcg J2469 Office 45 470 $368
Injection, fosaprepitant, 1 mg J1453 Office 19 3,000 $338
Injection, fluorouracil, 500 mg J9190 Office 16 140 $337
Injection, carboplatin, 50 mg J9045 Office 15 98 $283
Injection, paclitaxel, 1 mg J9267 Office 19 3,126 $247
Injection, leucovorin calcium, per 50 mg J0640 Office 16 46 $164

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

20 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record